Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths. Current cancer treatment modalities generally include chemotherapy, immunotherapy, radiation, and/or surgery. Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to serve as a potential chemosensitizer and radiotherapy enhancer.

Beyond Air's majority owned affiliate, Beyond Cancer, is developing treatment protocols using ultra-high nitric oxide concentrations to not only partially ablate primary tumors locally but also recognize and attack distant metastases systemically via stimulation of an antitumor immune response. For more information, visit www.beyondcancer.com.

Beyond Cancer Presentation